Ergomed PLC (LON:ERGO) insider Richard Barfield purchased 36,000 shares of the stock in a transaction on Friday, June 7th. The shares were purchased at an average cost of GBX 241 ($3.15) per share, with a total value of £86,760 ($113,367.31).
Shares of ERGO opened at GBX 266 ($3.48) on Thursday. Ergomed PLC has a one year low of GBX 145 ($1.89) and a one year high of GBX 258 ($3.37). The company has a quick ratio of 1.41, a current ratio of 1.48 and a debt-to-equity ratio of 0.02. The stock has a market cap of $123.80 million and a price-to-earnings ratio of -13.30.
Separately, Numis Securities raised Ergomed to a “buy” rating and set a GBX 230 ($3.01) price target for the company in a research report on Wednesday, April 10th.
Ergomed plc provides clinical research, and drug development and safety and medical information services in the United Kingdom and internationally. The company offers clinical development, trial management, and pharmacovigilance services for pharmaceutical and generics companies, as well as small and mid-sized drug development companies.
See Also: Net Margin
Receive News & Ratings for Ergomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ergomed and related companies with MarketBeat.com's FREE daily email newsletter.